Alderaan Biotechnology presents latest developments at SITC Congress
Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress. ALD2510 antibody…
read moreAlderaan Biotechnology develops therapeutic modalities targeting CD25 (IL2Ra) and CD160-TM for the treatment of cancers.
The company focuses on an ADC strategy that targets CD25+ cancer cells in Hematologic malignancies using a proprietary IL-2 sparing, CD25-specific antibody. In addition, Alderaan has generated unique proprietary antibodies against CD160-TM, a novel NK cell receptor overexpressed in solid cancers and in NK and T-cell lymphomas and Leukemias.
The company programs are based on the research of its founding scientists on the use of monoclonal antibodies targeting immune cells and tumour cells to treat cancers. The objective of Alderaan Biotechnology is to develop new therapeutic modalities targeting CD25, a molecule expressed by both Leukemic/lymphoma cells and suppressive Treg cells and CD160-TM, a novel marker overexpressed in solid tumours, with oncology as the sole indication focus.
Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress. ALD2510 antibody…
read more